uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Association of chromosome 19 to lung cancer genotypes and phenotypes
Show others and affiliations
2015 (English)In: Cancer Metastasis Review, ISSN 0167-7659, E-ISSN 1573-7233, Vol. 34, no 2, 217-226 p.Article, review/survey (Refereed) Published
Abstract [en]

The Chromosome 19 Consortium, a part of the Chromosome-Centric Human Proteome Project (C-HPP, ), is tasked with the understanding chromosome 19 functions at the gene and protein levels, as well as their roles in lung oncogenesis. Comparative genomic hybridization (CGH) studies revealed chromosome aberration in lung cancer subtypes, including ADC, SCC, LCC, and SCLC. The most common abnormality is 19p loss and 19q gain. Sixty-four aberrant genes identified in previous genomic studies and their encoded protein functions were further validated in the neXtProt database (). Among those, the loss of tumor suppressor genes STK11, MUM1, KISS1R (19p13.3), and BRG1 (19p13.13) is associated with lung oncogenesis or remote metastasis. Gene aberrations include translocation t(15, 19) (q13, p13.1) fusion oncogene BRD4-NUT, DNA repair genes (ERCC1, ERCC2, XRCC1), TGF beta 1 pathway activation genes (TGFB1, LTBP4), Dyrk1B, and potential oncogenesis protector genes such as NFkB pathway inhibition genes (NFKBIB, PPP1R13L) and EGLN2. In conclusion, neXtProt is an effective resource for the validation of gene aberrations identified in genomic studies. It promises to enhance our understanding of lung cancer oncogenesis.

Place, publisher, year, edition, pages
2015. Vol. 34, no 2, 217-226 p.
Keyword [en]
Proteins, Genes, Antibodies, mRNA, Mass spectrometry, Bioinformatics, Protein microarray, Human disease
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-261475DOI: 10.1007/s10555-015-9556-2ISI: 000358743300006PubMedID: 25982285OAI: oai:DiVA.org:uu-261475DiVA: diva2:851075
Note

Correction in: CANCER AND METASTASIS REVIEWS, Volume: 34, Issue: 2, Page: 227

DOI: 10.1007/s10555-015-9571-3

Available from: 2015-09-03 Created: 2015-09-01 Last updated: 2017-12-04Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Andrén, Per E.

Search in DiVA

By author/editor
Andrén, Per E.
By organisation
Department of Pharmaceutical Biosciences
In the same journal
Cancer Metastasis Review
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 346 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf